Dear Maryland Breast and Cervical Cancer Program Provider:

Thank you for providing breast cancer screening for uninsured or underinsured women aged 40-64 enrolled in the Maryland Breast and Cervical Cancer Program (BCCP). The Maryland BCCP is a grantee of the National Breast and Cervical Cancer Early Detection Program, funded by the Centers for Disease Control and Prevention (CDC). The policies of the national program are based on evidence in scientific literature and recommendations from national organizations such as the American Cancer Society, the National Comprehensive Cancer Network and the American College of Radiology.

We are pleased to enclose the revised “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis” developed by the Medical Advisory Committee for the BCCP to serve as guidelines for the screening and management of women receiving breast cancer screening through the BCCP and diagnostic services through the BCCP Expanded.

The Minimal Clinical Elements were updated based in part on the American Cancer Society Guidelines for Breast Cancer Screening, the National Comprehensive Cancer Network Breast Cancer Screening and Diagnosis Guidelines, and evidence based reviews of Breast Magnetic Resonance Imaging. They were completed before the November 17, 2009 release of the U. S. Preventive Services Task Force (USPSTF) Recommendation Statement on Screening for Breast Cancer. Despite the USPSTF Recommendations, the enclosed November 2009 Minimal Clinical Elements for Breast Cancer Detection and Diagnosis serve as the recommendations for the Maryland BCCP until further notice.
Some of the major changes include:

- Specific guidelines for when a woman should receive a screening mammogram versus a diagnostic mammogram;
- Clarification of the use of Magnetic Resonance Imaging (MRI) within BCCP.
- New Flow Sheets for management of findings

Enclosed are the revised “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis.”

We appreciate your cooperation in using these new guidelines. If you have any questions regarding the new “Minimal Clinical Elements for Breast Cancer Detection and Diagnosis” for the Maryland Breast and Cervical Cancer Program, please contact Diane Dwyer, M.D., Medical Director of the Center for Cancer Surveillance and Control (CCSC) at (410) 767-5088 or ddwyer@dhmh.state.md.us.

Sincerely,

[Signature]
Stanley Watkins, M.D.
Chairman, Medical Advisory Committee
Maryland Breast and Cervical Cancer Program

Enclosure

c: Donna Gugel, M.H.S., Director, CCSC
    Diane Dwyer, M.D., Medical Director, CCSC
    Courtney Lewis, M.P.H., Program Manager, BCCP
    Julia Mitchner, M.A.S., R.N., Nurse Program Consultant, BCCP
    Local BCCP Coordinators
    Local Health Officers
Minimal Clinical Elements for Breast Cancer Detection and Diagnosis
Maryland Breast and Cervical Cancer Program
Maryland DHMH, Center for Cancer Surveillance and Control

Goal:
The goal of the Minimal Clinical Elements for Breast Cancer Detection and Diagnosis is to provide clients of the Maryland Breast and Cervical Cancer Program (BCCP) with optimal, up-to-date screening for breast cancer and management of findings.

Objective:
- To provide clinical guidelines for breast cancer screening and diagnostic testing including interpretation and management of results of clinical breast examination, mammography, and diagnostic testing.
- To outline appropriate management and approved indications for procedure payment.

Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program—Breast Cancer Minimal Clinical Elements

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Maryland Breast and Cervical Cancer Program (BCCP)— Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Expanded Diagnostic Testing</td>
<td></td>
</tr>
<tr>
<td>A. BCCP Eligibility, and Procedures for Screening or Initial Testing</td>
<td>3</td>
</tr>
<tr>
<td>B. Eligibility for Diagnostic Testing in the BCCP Expanded Services</td>
<td>4</td>
</tr>
<tr>
<td>II. Findings, Management of Results, Additional Procedures, and Program Coverage</td>
<td></td>
</tr>
<tr>
<td>A. Results and Reports</td>
<td>5</td>
</tr>
<tr>
<td>B. Management of Findings of CBE, Initial Mammogram, and Testing</td>
<td>6</td>
</tr>
<tr>
<td>C. Additional Procedures and Program Coverage</td>
<td>6</td>
</tr>
<tr>
<td>Attachment A</td>
<td>9</td>
</tr>
<tr>
<td>Flow Charts of the Maryland Breast and Cervical Cancer Program: Management of Clinical Breast Examination and Mammogram Results</td>
<td></td>
</tr>
<tr>
<td>I. Management when the Clinical Breast Exam is Normal/Benign</td>
<td>10</td>
</tr>
<tr>
<td>II. Management when the Clinical Breast Exam is Abnormal</td>
<td>11</td>
</tr>
</tbody>
</table>
Members of the Breast Cancer Subcommittee of the
BCCP Medical Advisory Committee

Stanley Watkins, M.D., Chairman
Hematologist/Oncologist
Annapolis Medical Specialists
Assistant Professor of Oncology, The Johns Hopkins School of Medicine (part time)

Cecilia Brennecke, M.D.
Medical Director, Johns Hopkins Greenspring Radiology Center
American Radiology

Robert Brookland, M.D.
Radiation Oncology/Radiation Therapy
Greater Baltimore Medical Center

Stacy Garrett-Ray, M.D., M.P.H., M.B.A.
Medical Director
University of Maryland
UniversityCare Medical Center

Kathy J. Helzlsouer, M.D., M.H.S.
Director, Prevention and Research
The Weinberg Center for Women’s Health and Medicine
Mercy Hospital Center

Nagi Khouri, M.D.
Associate Professor of Radiology and Radiological Science
Associate Professor, Oncology Center
Johns Hopkins Medical Institutes

Lorraine Tafra, M.D.
Breast Surgery
Anne Arundel Medical Center

Staff for the Breast Cancer Subcommittee
Center for Cancer Surveillance and Control, Maryland Dept. of Health and Mental Hygiene
Donna Gugel, M.H.S., Director, CCSC
Diane Dwyer, M.D., Medical Director, CCSC
Courtney Lewis, M.P.H., Program Manager, BCCP
Julia Mitchner, M.A.S., R.N., Nurse Program Consultant, BCCP
Detection and Management of Breast Abnormalities in the Breast and Cervical Cancer Program

Breast Cancer Minimal Clinical Elements (MCE)

I. Maryland Breast and Cervical Cancer Program (BCCP)—Eligibility for Screening, Procedures for Screening or Initial Testing, and Eligibility for Expanded Diagnostic Testing

A. BCCP Eligibility, and Procedures for Screening or Initial Testing

1. A woman is eligible for breast cancer screening with clinical breast examination (CBE) and mammogram in the BCCP regardless of symptoms, risk factors, or prior breast cancer/findings if she:
   a. Is 40 – 64 years old or 65+ without Medicare Part B;
   b. Meets income eligibility of household income ≤250% of the Federal Poverty Guideline;
   c. Has no health insurance, has no health insurance that covers breast cancer screening, or has coverage but has not met deductible for the year; and
   d. Has not had bilateral mastectomies.

2. A woman should have a diagnostic mammogram if a woman has:
   a. A CBE with results that include:
      i. Nipple discharge that is:
         (a) Bloody;
         (b) Crystal clear (like water); or
         (c) Any other color or clarity (for example, yellow, white, milky, gray, green) if the discharge is unilateral, single duct, and spontaneous.
      ii. Discrete palpable mass—suspicious for cancer;
      iii. Nipple/areolar scaliness; or
      iv. Skin dimpling/retraction;
   b. Prior unilateral mastectomy;
   c. Prior history of breast cancer (in situ or invasive, in patient who has not had bilateral mastectomies); or
   d. A recommendation for a diagnostic mammogram from the Medical Case Manager.

3. A woman should have a screening mammogram as the annual exam if the woman has:
   a. A CBE with Normal findings or a CBE with Benign findings, including:
      i. Nipple discharge that doesn’t meet the definition for diagnostic mammogram (2., a., i., above);
      ii. Breast implant(s);
      iii. Fibrocystic changes;
      iv. Mastitis;
v. “Lumpy” breasts;
vi. Family history of breast cancer (premenopausal breast cancer in sister/mother); or
vii. Prior benign biopsy (within past year) when surgeon or radiologist recommends screening mammogram.
b. A history of negative screening mammogram(s) (American College of Radiology, Breast Imaging and Database Reporting System [BI-RADS] category 1, negative, or BI-RADS 2, benign finding);
c. No prior mastectomy; and

d. No prior breast cancer.

4. CBE should be performed within the three months prior to the screening mammogram.

5. Each breast should be examined including the retroareolar and peripheral areas and the upper lateral quadrant into the axilla.

6. The preferred method of CBE is the strip technique using three levels of pressure in small circular motions with pad of three middle fingers without lubrication (MammaCare® method).

B. Eligibility for Diagnostic Testing in the BCCP Expanded Services

A woman or man is eligible for breast cancer diagnostic testing in the BCCP Expanded Services if s/he:

1. Is 40 – 64 years old, or 65+ without Medicare Part B;

2. Meets income eligibility of ≤250% of the Federal Poverty Guideline;

3. Has no health insurance, has no health insurance that covers breast cancer diagnostic testing/visits, or has coverage but has not met deductible for the year;

4. Has not had bilateral mastectomies; and

5. Provides the BCCP with a recommendation from a clinician for diagnostic workup and test results of:
   a. A CBE requiring further diagnosis (see I. A. 2. a.);
   b. A mammogram requiring further diagnosis;
   c. Ultrasound abnormal finding other than simple cyst(s); or
   d. Persistent, unexplained, localized pain in the breast with a negative mammogram.
II. Findings, Management of Results, Additional Procedures, and Program Coverage

A. Results and Reports

1. **CBE findings** should be reported as:
   a. Normal exam
   b. Benign findings
   c. Bloody/serous nipple discharge
   d. Discrete palpable mass—suspicious for cancer
   e. Nipple/areolar scaliness
   f. Skin dimpling/retraction

2. CBE should report whether there are breast implants; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.

3. CBE should report whether the patient has had a lumpectomy or a mastectomy and which breast was affected; however, this finding would be categorized as a “Benign finding” if no other abnormalities were found.

4. **Mammogram findings** should be reported using American College of Radiology® BI-RADS® (Breast Imaging-Reporting and Database System) Assessment Categories:
   a. **Assessment is Incomplete**
      
      0  Need Additional Imaging Evaluation and/or Prior Mammograms for Comparison

   b. **Assessment is Complete – Final Categories**

   1  Negative
   2  Benign Finding(s)
   3  Probably Benign Finding – Initial Short-Interval Follow-Up Suggested
   4  Suspicious Abnormality – Biopsy Should Be Considered
   5  Highly Suggestive of Malignancy – Appropriate Action Should Be Taken
   6  Known Biopsy-Proven Malignancy – Appropriate Action Should Be Taken (Category reserved for lesions identified on imaging study with biopsy proof of malignancy prior to definitive therapy)

   Ref. The American College of Radiology BI-RADS® ATLAS and MQSA: Frequently Asked Questions (Updated: 7/1/09)

5. **Breast composition on mammogram** should be described for all patients using the following patterns:
   a. The breast is almost entirely fat (<25% glandular)
   b. There are scattered fibroglandular densities (approximately 25-50% glandular)
c. The breast tissue is heterogeneously dense, which could obscure detection of small masses (approximately 51-75% glandular)
d. The breast tissue is extremely dense. This may lower the sensitivity of mammography (>75% glandular).

Ref. 2003 ACR BI-RADS® Atlas

6. Ultrasound definitions: The terms “simple cyst,” “complicated cyst,” and “complex cyst” are defined by the radiologist and stated in the report of an ultrasound examination.

7. The radiologist’s diagnostic workup/evaluation report should include the results of the diagnostic mammogram, ultrasound (when performed), CBE, and the correlation of each test with each other.

B. Management of Findings of CBE, Initial Mammogram, and Testing


2. A woman with persistent, unexplained, localized pain in the breast should be evaluated by a breast specialist or surgeon.

3. If a radiologist recommends obtaining results or copies of prior mammograms following a BI-RADS category 0 result, local programs should assist in obtaining the results or copies.

4. Image-guided percutaneous needle biopsy is the diagnostic procedure of choice for image-detected abnormalities, with few exceptions.

5. When a non-palpable or questionably palpable mass that was found on imaging is excised, the specimen should be verified by using the appropriate imaging modality while the patient is still in the operating room.

6. At least one breast tissue specimen positive for cancer should be tested for tumor markers (e.g. estrogen/progesterone receptors, her2neu etc.) to guide clinical management.

C. Additional Procedures and Program Coverage

1. Providers should consult with the local BCCP for questions about coverage for payment of procedures.

2. Magnetic Resonance Imaging (MRI)
   a. The DHMH BCCP will not reimburse for MRI for breast cancer screening.
b. If recommended by the managing physician, the expanded diagnostic BCCP **will reimburse** for a MRI of the breast for:
   i. Extent of disease in the ipsilateral breast in patients with a recent diagnosis of breast cancer;
   ii. Screening of the contralateral breast in women with a current, newly diagnosed, unilateral breast cancer;
   iii. Evaluation of patients undergoing current neoadjuvant chemotherapy for breast cancer;
   iv. Positive margins after surgery for breast malignancy; or
   v. Chest wall invasion suspected.

c. The BCCP **will not reimburse** for MRI of the breast for:
   i. Surveillance of breast findings (for example, the program will not reimburse for MRI follow-up every 3-6 months to a surgical consult of “benign findings”);
   ii. Problem solving for inconclusive clinical or mammographic findings; or
   iii. Evaluation of silicone breast implant integrity.

2. The BCCP will pay for a surgical or breast specialist consultation for a woman who has a negative mammogram but who has persistent, unexplained, localized pain in the breast.

3. The BCCP will pay for a maximum of two consults with the same surgeon in one year for the same benign breast problem.
Attachment A

Flow Charts
of the Maryland Breast and Cervical Cancer Program:

Management of Clinical Breast Examination and Mammogram Results

I. Management when Clinical Breast Examination is Normal/Benign Findings

II. Management when Clinical Breast Examination is Abnormal
I. Management of Clinical Breast Exam and Mammogram Results: Normal/Benign Clinical Breast Exam

Clinical Breast Examination: Normal or Benign Findings

Women who:
- Are asymptomatic**
- Have implant(s), fibrocystic changes, mastitis, 'lumpy' breasts,
  - history of breast cancer (premenopausal breast cancer in
    sister/mother), or prior benign biopsy (within past year) when surgeon
    or radiologist recommends screening mammogram.

Women who have:
- Unilateral mastectomy;
- Previous breast cancer (in situ or invasive); or
- Medical Case Manager recommendation for Diagnostic Mammogram**

Screening mammogram

Diagnostic mammogram

Mammogram Results

- BI-RADS 0: Needs additional imaging evaluation
  - Follow up per radiologist:
    - Diagnostic work-up (spot compression, magnification, special views, ultrasound, aspiration...)

- BI-RADS 1: Negative
  - Annual follow-up: CBE with screening mammogram (if asymptomatic)

- BI-RADS 2: Benign Finding
  - Follow up per radiologist (usually 6 month repeat)

- BI-RADS 3: Probably benign - short interval follow-up suggested
  - Radiologist communicates findings to the patient, the referring physician
  - Refer to surgeon or breast specialist

- BI-RADS 4: Suspicious Abnormality - Biopsy Should Be Considered
  - BI-RADS 4 AND Negative biopsy (that is, biopsy is not cancer, LCIS+ or atypical ductal hyperplasia)
    - Radiologist and primary care provider recommend next steps
  - BI-RADS 4 OR 5 with biopsy that is LCIS+ or atypical ductal hyperplasia
    - Further follow-up per surgeon
  - BI-RADS 4 OR 5 with: Negative biopsy OR biopsy that is LCIS+ or atypical ductal hyperplasia
    - Further follow-up per surgeon

- BI-RADS 5: Highly Suggestive of Malignancy - Appropriate Action Should Be Taken
  - Positive biopsy (invasive cancer or DCIS+)
    - Surgeon performs biopsy
  - Cancer (invasive or DCIS+) on prior biopsy; surgeon performs no additional biopsy

* The BCCP will reimburse for a maximum of two consults per year to the same surgeon for the same benign breast finding

** A woman with persistent, unexplained, localized pain in the breast should be evaluated by a breast specialist or surgeon (see II. B. 2.)

+ DCIS: Ductal carcinoma in situ

LCIS: Lobular carcinoma in situ
II. Management of Clinical Breast Exam and Mammogram Results: Abnormal Clinical Breast Exam

Clinical Breast Examination: Abnormal (other than Normal or Benign Finding) **

Diagnostic mammogram (always); with Ultrasound, if recommended

CBE, Mammogram, and Ultrasound Results

BI-RADS 0
- Needs additional imaging evaluation
  Follow up per radiologist:
  - Diagnostic work-up (spot compression, magnification, special views, ultrasound, aspiration...)

BI-RADS 1, 2, or 3
- Simple cyst(s), or
- Complicated cyst(s)

No aspiration of cyst
Aspirate cyst
Clear fluid
Bloody fluid

BI-RADS 2: Benign Finding
Annual follow-up: CBE with screening mammogram (if asymptomatic)

BI-RADS 3: Probably benign—short interval follow-up suggested
Follow up per radiologist (usually 6 month repeat)

Any clinical finding and:
- Complex cyst(s);
- BI-RADS 4: Suspicious Abnormality – Biopsy Should Be Considered; or
- BI-RADS 5: Highly Suggestive of Malignancy–Appropriate Action Should Be Taken

Radiologist communicates findings to the patient, the referring physician

Refer to surgeon or breast specialist

Image-guided biopsy

Positive biopsy (invasive cancer or DCIS+)
BI-RADS 5: and Negative biopsy OR
BI-RADS 4 of 5 and biopsy that is LCIS+ or atypical ductal hyperplasia

BI-RADS 4 AND Negative biopsy (that is, biopsy is not cancer, LCIS+ or atypical ductal hyperplasia)

Radiologist and primary care provider recommend next steps

Management and Treatment of Cancer
Surgeon stages and initially manages breast cancer;
- Stage 0 must be offered oncologist consult
- Stage 1-4 must see oncologist

Further follow-up per surgeon*

No cancer documented; surgeon does not perform biopsy

Further follow-up per surgeon*

Cancer (invasive or DCIS+) on prior biopsy; surgeon does not perform additional biopsy

Positive biopsy (invasive cancer or DCIS+)

Negative biopsy OR
Biopsy that is LCIS+ or atypical ductal hyperplasia

Further follow-up per surgeon*

* The BCCP will reimburse for a maximum of two consults per year to the same surgeon for the same benign breast finding

** "Abnormal" Clinical Breast Exam Includes:
- Nipple discharge that is bloody, crystal clear, or of any color if unilateral, single duct, and spontaneous;
- Discrete palpable mass—suspected for cancer
- Nipple/areolar scaliness
- Skin dimpling or retraction

+ DCIS: Ductal carcinoma in situ
LCIS: Lobular carcinoma in situ

Maryland Breast Cancer Minimal Clinical Elements, 2009